(Q37917911)

25 August 2017

1 reference

title

Antibody drug conjugates - Trojan horses in the war on cancer (English)

1 reference

25 August 2017

1 reference

U Iyer

1

1 reference

PubMed ID

21843648

25 August 2017

V J Kadambi

series ordinal

2

1 reference

PubMed ID

21843648

25 August 2017

language of work or name

1 reference

6 August 2011

1 reference

Journal of Pharmacological and Toxicological Methods

25 August 2017

1 reference

25 August 2017

64

1 reference

25 August 2017

207-212

1 reference

25 August 2017

3

1 reference

Potent antibody therapeutics by design

25 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Recent developments in the maytansinoid antitumor agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Development of potent monoclonal antibody auristatin conjugates for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Targeting RAS signalling pathways in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Process economics of industrial monoclonal antibody manufacture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Complement function in mAb-mediated cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Mode of action of docetaxel - a basis for combination with novel anticancer agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Microtubules and actin filaments: dynamic targets for cancer chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Continuous cultures of fused cells secreting antibody of predefined specificity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Antibody-maytansinoid conjugates designed to bypass multidrug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Calicheamicins, a novel family of antitumor antibiotics. 3. Isolation, purification and characterization of calicheamicins beta 1Br, gamma 1Br, alpha 2I, alpha 3I, beta 1I, gamma 1I and delta 1I

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

inferred from DOI database lookup

7 January 2021

based on heuristic

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Eradication of large colon tumor xenografts by targeted delivery of maytansinoids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Managing taxane toxicities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Pathways of apoptotic and non-apoptotic death in tumour cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Novel therapeutic strategies to selectively kill cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Phase II trial of dolastatin-10 in patients with advanced breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Antibody-based therapeutics to watch in 2011.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Monoclonal antibody successes in the clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

mAbs: a business perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

7 January 2021

The problem with potency

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Potent antibody drug conjugates for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Monoclonal antibodies: versatile platforms for cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

Arming antibodies: prospects and challenges for immunoconjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.07.005

10.1016/J.VASCN.2011.07.005

7 January 2021

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

21843648